Business Wire

American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes and established cardiovascular disease in new Expert Consensus Decision Pathway

Jaa

A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The recommendation, part of the ACC’s first Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in adults with type 2 diabetes, was released today and published online in the Journal of the American College of Cardiology.1 Empagliflozin is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181126005751/en/

The recommendation of empagliflozin is based on evidence from the landmark EMPA-REG OUTCOME® trial, which investigated the effects of empagliflozin compared with placebo when added to standard of care in adults with type 2 diabetes and established cardiovascular disease.2 In addition to the ACC Expert Consensus Decision Pathway, the American Diabetes Association® (ADA) and European Association for the Study of Diabetes (EASD) recently published a Consensus Report recommending SGLT2 inhibitors, such as empagliflozin, to help manage cardiovascular outcomes in patients with type 2 diabetes.3 Empagliflozin is also the only SGLT2 inhibitor recommended in the ADA 2018 Standards of Medical Care in Diabetes for reducing the risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease.4 Worldwide, more than 50 treatment guidelines have been updated to include findings from the EMPA-REG OUTCOME trial® in their endorsement of type 2 diabetes treatments with proven cardiovascular benefits.5

“People with type 2 diabetes are at increased risk of serious cardiovascular complications and events, even when their blood sugar is under control, which is why a focus on reducing cardiovascular risk in people with diabetes is critical,” said Waheed Jamal, M.D., Corporate Vice President and Head of CardioMetabolic Medicine, Boehringer Ingelheim. “The ACC Expert Consensus Decision Pathway, along with the Consensus Report from the ADA and EASD, all now recommend that comprehensive cardiovascular care for adults with type 2 diabetes and established cardiovascular disease includes a treatment shown to improve cardiovascular outcomes in this population, such as empagliflozin. These recommendations reflect a fundamental shift in the management of type 2 diabetes, moving beyond glucose control to a broader strategy of comprehensive cardiovascular risk reduction.”

The 2018 ACC Expert Consensus Decision Pathway emphasises the need for a collaborative treatment approach by healthcare providers to reduce cardiovascular risk and improve survival in people with type 2 diabetes, a growing public health epidemic.1 People with diabetes are up to four times more likely to develop cardiovascular disease than those without diabetes, and cardiovascular disease is the leading cause of death associated with diabetes.6,7

The ACC Expert Consensus Decision Pathway’s recommendation of empagliflozin, along with those of the ADA and EASD, represents a shift towards a comprehensive and team-based approach for managing the overall health of people with type 2 diabetes. The ACC encourages cardiologists to work as part of a broad healthcare provider team including primary care, internal medicine and endocrinology physicians, as well as nurse practitioners, physician assistants, diabetes educators and pharmacists, to improve the care and outcomes of people with type 2 diabetes.1

“The EMPA-REG OUTCOME trial® ushered in a new era for managing type 2 diabetes. Now, cardiovascular risk reduction is prioritised as a primary goal of diabetes management,” said Sherry Martin, M.D., Vice President, Medical Affairs, Lilly. “With the adoption of the ACC’s Expert Consensus Decision Pathway and ADA-EASD Consensus Report, the cardiology community will have an important role as part of the healthcare team managing cardiovascular risk in people with type 2 diabetes.”

About EMPA-REG OUTCOME ® ( NCT01131676 ) 2
EMPA-REG OUTCOME® was a long-term, multicenter, randomised, double-blind, placebo-controlled trial of more than 7,000 patients from 42 countries with type 2 diabetes and established cardiovascular disease.

The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

The overall safety profile of empagliflozin was consistent with that of previous trials.

About Diabetes and Cardiovascular Disease
More than 425 million people worldwide have diabetes, of which over 212 million are estimated to be undiagnosed.8 By 2045, the number of people with diabetes is expected to rise to 629 million people worldwide.8 Type 2 diabetes is the most common form of diabetes, responsible for around 90 percent of diabetes cases in high-income countries.8 Diabetes is a chronic condition that occurs when the body either does not properly produce, or use, the hormone insulin.8

Due to the complications associated with diabetes, such as high blood sugar, high blood pressure and obesity, cardiovascular disease is a major complication and the leading cause of death associated with diabetes.9,10 People with diabetes are two to four times more likely to develop cardiovascular disease than people without diabetes.10 In 2017, diabetes caused four million deaths worldwide, with cardiovascular disease as the leading cause.8 Approximately 50 percent of deaths in people with type 2 diabetes worldwide are caused by cardiovascular disease.7,11

Having a history of diabetes at age 60 can shorten a person’s life span by as much as six years compared with someone without diabetes. And having both diabetes and a history of heart attack or stroke by age 60 can shorten a person’s life span by as much as 12 years compared with someone without these conditions.12

More than 50 guidelines have been updated to endorse type 2 diabetes agents with proven cardiovascular benefits since 2016, including a recent Consensus Report initiated by the American Diabetes Association® and European Association for the Study of Diabetes, recommending that, in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, SGLT2 inhibitors (such as empagliflozin) or GLP1 receptor agonists with proven cardiovascular benefits are recommended as part of glycaemic management.13,14

About Empagliflozin
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor and the first type 2 diabetes medicine to include cardiovascular death risk reduction data in the label in several countries.15,16,17

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). Empagliflozin induces changes to the sugar, salt and water metabolism in the body that may contribute to the reductions in cardiovascular death observed in the EMPA-REG OUTCOME® trial.

Please click on the following link for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/press-release/empa-acc-expert-consensus-decision-pathway

Contact information

Dr Petra Kienle
Product Communication Manager
Boehringer Ingelheim
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 143877

Greg Kueterman
Director of Communications
Lilly Diabetes and Lilly USA
Email: kueterman_gregory_andrew@lilly.com
Phone: +1 (317) 432-5195

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Age Matters: PMI Calls All Tobacco and E-Cigarette Companies To Do Their Part to Guard Against Youth Nicotine Use23.4.2019 20:29:00 EESTTiedote

Philip Morris International Inc. (PMI) (NYSE: PM) today reaffirmed its vision for the future: To achieve a smoke-free world; that is, one without cigarettes. For the hundreds of millions of men and women globally who will otherwise continue to smoke, PMI’s goal is to switch them to nicotine-containing products that are scientifically substantiated as better choices than continuing to smoke. Our strong belief—if you don’t smoke, don’t start—begins with a continued and robust focus on preventing youth from beginning to smoke or use nicotine products. “Given the rapid pace of innovation in the tobacco products space, we are emphatic that youth should not use any tobacco- or nicotine-containing product. Nicotine is addictive. It is not risk-free, and it poses particular risks for adolescents. We know that great care must be taken to achieve our smoke-free goal. Youth should not become nicotine users. Former smokers and never smokers should not return to, or pick up, the tobacco or nicotine

Personalis, Inc. to Present at European NeoAG Summit 201923.4.2019 18:00:00 EESTTiedote

Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at European NeoAG Summit 2019 in Amsterdam on April 24th at 2:30 PM CEST. The presentation, entitled “ImmunoID NeXT Platform: Improving Neoantigen Prediction, TME Assessment, and ctDNA Detection for Vaccine Development,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™. In addition to an overview, the presentation will highlight innovative genomics methods for more comprehensive assessment of neoantigens, which include improving neoantigen-to-MHC binding prediction and ranking and assessing TME/TCR and tumor escape mechanisms that may impact vaccine response. ImmunoID NeXT is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays i

Keio Plaza Hotel Tama Opens My Melody, Little Twin Stars Rooms on June 15, 2019 - Sweet Dreams in Our Hello Kitty and Sanrio Character Rooms23.4.2019 17:05:00 EESTTiedote

The Keio Plaza Hotel Co., Ltd., one of Japan’s most prestigious hotel companies operating hotels located in the Shinjuku district of Tokyo and other locations, is proud to announce the strengthening of its collaborative relationship with Sanrio Co., Ltd. (Headquarters: Shinagawa, Tokyo, President and CEO: Shintaro Tsuji) to expand facilities and services featuring “Hello Kitty” and other Sanrio characters at our Keio Plaza Hotel Tama. Our Tama Hotel will renovate a total of four additional rooms, including two rooms each in the themes of “My Melody” and “Little Twin Stars” (Kiki and Lala) who have been adored by fans around the world since their creation in 1975, to be opened on Saturday June 15, 2019, and thereby become the world’s first hotel to operate rooms in these themes on a regular basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005311/en/ New Sanrio characters rooms, including two rooms each in the theme

Project Management Institute, Inc. (PMI) Delivers Full Suite of Certification Exams in Over 5,000 Locations Through Expanded Testing Agreement with Pearson VUE23.4.2019 17:00:00 EESTTiedote

Project Management Institute, Inc. (PMI), the leading not-for-profit professional membership association for the project management profession, and Pearson VUE, a global leader in the computer-based testing industry, have announced an expanded, multi-year agreement that will offer more testing options for candidates looking to earn PMI certifications at all stages of their career. The new agreement will offer candidates access to even more PMI certification tests as well as more flexibility in their testing location options, thanks to Pearson VUE’s global network of testing centers and online proctoring solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190423005149/en/ Beginning July 1, 2019, seven additional PMI programs, including the Project Management Professional (PMP)® – renowned as the global gold standard for project management professionals – will become available to professionals around the globe through Pe

Andersen Global Marks Growth to 50 Countries with Collaborating Firm in Zambia23.4.2019 16:30:00 EESTTiedote

Andersen Global announced it achieved a new milestone today in its continuing growth with the addition of Mulenga Mundashi Kasonde Legal Practitioners (MMKLP). MMKLP, a law firm in Zambia, has signed a Collaboration Agreement with Andersen Global. The international association now has presence in 50 countries through its member and collaborating firms. Led by five partners, MMK has been advising clients in corporate mergers and acquisitions, tax, litigation, and labor and industrial resolutions since 1999. The firm is now one of the largest law firms in Zambia in its twentieth year. The collaborating firm will be the eleventh location in Africa for Andersen Global. “We’ve had the opportunity to advise on some of the highest profile financial events for Zambia in modern history,” said Micheal Mundashi, MMKLP Managing Partner. “One of the things that keeps us moving forward is the desire to provide even more for our local and international clients. Collaborating with Andersen Global will

Aventri Introduces Uber Vouchers to Deliver New Transportation Options23.4.2019 16:00:00 EESTTiedote

Event management software (EMS) leader Aventri today announces a new partnership with Uber for Business. Aventri is the first EMS provider to launch a partnership with Uber for Business to offer customers the opportunity to utilize Uber Vouchers. Uber Vouchers’ web-based tool allows event organizers to provide VIP treatment to attendees with stress-free, reliable transportation to and from events. “We’re always looking for new partners to help our customers streamline events and add value,” said Brad Langley, vice president of channel and partner management for Aventri. “Uber for Business fits the bill. Using Uber Vouchers, organizers spend less time arranging logistics for moving groups, and their guests can come and go at a time that’s convenient for them.” Using Uber Vouchers, organizers can enhance the journey for themselves and their guests. Some benefits include: Customized Control: Organizers can easily create and manage campaigns online by setting parameters for pickup, drop-of

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme